TrialAnnals of clinical and translational neurology2022

A double-blind, randomized, placebo-controlled phase 2 trial evaluating the selective dihydroorotate dehydrogenase inhibitor vidofludimus calcium in relapsing-remitting multiple sclerosis.

Robert J Fox et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.